- Home
- Biomedical Sciences
- General Biomedical Engineering
- Handbook of Clinical Nanomedicine (2 Volume Set)
Handbook of Clinical Nanomedicine (2 Volume Set)
edited by Raj Bawa, Gerald F. Audette, Israel Rubinstein and Brian E. Reese
- Format: eBook
- ISBN: 9789814411660
- Subject: General Biomedical Engineering
- Published: February 2015
For Course Instructors: Inspection Copies
“Dr. Bawa and his team have meticulously gathered the distilled experience of world-class researchers, clinicians and business leaders addressing the most salient issues confronted in product concept development and translation. Knowledge is power, particularly in nanomedicine translation, and this handbook is an essential guide that illustrates and clarifies our way to commercial success.”
Gregory Lanza, MD, PhD - Washington University Medical School, USA
“This is an outstanding, comprehensive volume that crosscuts disciplines and topics fitting individuals from a variety of fields looking to become knowledgeable in medical nanotech research and its translation from the bench to the bedside.”
Shaker A. Mousa, PhD, MBA - Albany College of Pharmacy and Health Sciences, USA
“Masterful! This handbook will have a welcome place in the hands of students, educators, clinicians and experienced scientists alike. In a rapidly evolving arena, the authors have harnessed the field and its future by highlighting both current and future needs in diagnosis and therapies. Bravo!”
Howard E. Gendelman, MD - University of Nebraska Medical Center, USA
“It is refreshing to see a handbook that does not merely focus on preclinical aspects or exaggerated projections of nanomedicine. Unlike other books, this handbook not only highlights current advances in diagnostics and therapies but also addresses critical issues like terminology, regulatory aspects and personalized medicine.”
Gert Storm, PhD - Utrecht University, The Netherlands
“The distinguished editors have secured contributions from the leading experts in nanomedicine law, business, regulation and policy. This handbook represents possibly the most comprehensive and advanced collections of materials on these critical topics. An invaluable standard resource.”
Gregory N. Mandel, JD - Temple University Beasley School of Law, USA
“This is an outstanding volume for those looking to become familiar with nanotechnology research and its translation from the bench to market. Way ahead of the competition, a standard reference on any shelf.”
Shaker A. Mousa, PhD, MBA - Albany College of Pharmacy, USA
“The editors have gathered the distilled experience of leaders addressing the most salient issues confronted in R&D and translation. Knowledge is power, particularly in nanotechnology translation, and this handbook is an essential guide that illustrates and clarifies our way to commercial success.”
Gregory Lanza, MD, PhD - Washington University Medical School, USA
“The title of the handbook reflects its broad-ranging contents. The intellectual property chapters alone are worthy of their own handbook. Dr. Bawa and his coeditors should be congratulated for gathering the important writings on nanotech law, business and commercialization.”
Richard J. Apley, JD - Litman Law Offices/Becker & Poliakoff, USA
“It is clear that this handbook will serve the interdisciplinary community involved in nanomedicine, pharma and biotech in a highly comprehensive way. It not only covers basic and clinical aspects but the often missing, yet critically important, topics of safety, risk, regulation, IP and licensing. The section titled ‘Perspectives and Editorials’ is superb.”
Yechezkel (Chezy) Barenholz, PhD - Hebrew University-Hadassah Medical School, Israel
Pan Stanford Series on Nanomedicine
Diversity within the broad and evolving arena of nanomedicine and nanopharma is reflected in the expertise of the distinguished contributing authors. The chapters contain key words, figures in full-color and an extensive list of references. As compared to texts on the market, each handbookin the series is comprehensive and intended to be a stand‐alone reference resource, presented in a user-friendly format for easy access. The editors have skillfully curated each chapter to reflect the most relevant and current information possible. The range of topics covered as well as the multidisciplinary approach of the handbookswill attract a global audience. The handbooks are essential reading for both the novice and expert in fields ranging from medicine, biotechnology, pharmaceutical sciences, engineering, FDA law, intellectual property, policy, future studies, ethics, licensing, commercialization, risk analysis, and toxicology.
Handbook of Clinical Nanomedicine. Vol. 1. Nanoparticles, Imaging, Therapy, and Clinical Applications, Raj Bawa, PhD, Gerald F. Audette, PhD, and Israel Rubinstein, MD (Editors)
This handbook (55 chapters) provides a comprehensive roadmap of basic research in nanomedicine as well as clinical applications. However, unlike other texts in nanomedicine, it not only highlights current advances in diagnostics and therapeutics but also explores related issues like nomenclature, historical developments, regulatory aspects, nanosimilars and 3D nanofabrication. While bridging the gap between basic biomedical research, engineering, medicine and law, the handbook provides a thorough understanding of nano’s potential to address (i) medical problems from both the patient and health provider's perspective, and (ii) current applications and their potential in a healthcare setting.
Handbook of Clinical Nanomedicine. Vol. 2. Law, Business, Regulation, Safety, and Risk, Raj Bawa, PhD (Editor), Gerald F. Audette, PhD, and Brian E. Reese, PhD, MBA, JD (Assistant Editors)
This unique handbook (60 chapters) examines the entire “product life cycle,” from the creation of nanomedical products to their final market introduction. While focusing on critical issues relevant to nanoproduct development and translational activities, it tackles topics such as regulatory science, patent law, FDA law, ethics, personalized medicine, risk analysis, toxicology, nano-characterization and commercialization activities. A separate section provides fascinating perspectives and editorials from leading experts in this complex interdisciplinary field.
About the Series Editor
Dr. Raj Bawa is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm based in Ashburn, VA, USA. He is an entrepreneur, professor, researcher, inventor, and registered patent agent licensed to practice before the U.S. Patent and Trademark Office. Trained as a biochemist and microbiologist, he is currently an adjunct professor of biological sciences at Rensselaer Polytechnic Institute in Troy, NY, as well as a scientific advisor to Teva Pharmaceutical Industries, Israel. He has authored over 100 publications, coedited 4 texts and serves on the editorial board of 17 journals.
For more information on the individual volumes, please click on the following links:
1) Volume 1
2) Volume 2
Raj Bawa, PhD, MD, is president of Bawa Biotech LLC (founded 2002), a biotech/pharma consultancy and patent law firm based in Ashburn, Virginia. Trained as a microbiologist and biochemist, he is an inventor, author, entrepreneur, professor, and registered patent agent (since 2002) licensed to practice before the US Patent & Trademark Office. He is currently scientific advisor to Teva Pharmaceutical Industries, Israel (since 2010); visiting research scholar at Pharmaceutical Research Institute of Albany Pharmacy, Albany, New York; and full professor (adjunct) at NOVA in Annandale, Virginia (since 2004). He is VP/chief IP officer at Guanine, Inc., in Rensselaer, New York (since 2017), a company focused on rapid, accurate detection of infective pathogens. Dr. Bawa has served as a principal investigator of various NCI research grants, and most recently as a principal investigator of a CDC grant to develop an assay for carbapenemase resistant bacteria. Previously, he was an adjunct professor at Rensselaer Polytechnic Institute, Troy, New York, from 1998 to 2018. He held various positions at the US Patent Office, including primary examiner from 1996 to 2002. He earned a BSc (Honors School) in microbiology, MS in cancer biology, PhD in biophysics/biochemistry, and MD. Currently, he is a life member of Sigma Xi, cochair of the nanotech and precision medicine committees of the American Bar Association and founding director of the American Society for Nanomedicine (established 2008). He has authored over 100 publications, edited 10 texts, and serves on the editorial boards of numerous peer-reviewed journals, including serving as an associate editor of Nanomedicine (Elsevier).
Gerald F. Audette, PhD, has been a faculty member at York University in Toronto, Canada, in the Department of Chemistry since 2006. Currently he is associate professor in the department and a member of the Centre for Research on Biomolecular Interactions at York University. Dr. Audette is the co-editor of volumes 1-4 of the Pan Stanford Series on Nanomedicine and is a subject editor of structural chemistry and crystallography for the journal FACETS.